Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 83.68

+0.1%

Nov 28 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (1116)	7/18/2005 10:05:51 AM
From: Jibacoa	Read Replies (1) of 3722

ARQL Is making a 52 wks. H after it said that preclinical data showed that direct activation of the human checkpoint kinase 2, or Chk2, killed cancer cells. Activating Chk2 in the absence of chemotherapy led to the death of cancer cells."This study showed that the activation of checkpoints independently and directly led to cancer cell death." Checkpoint activation, is the central focus of the company's approach to oncology drugs and the basis for its clinical testing of ARQ 501,which they have partnered with Roche. bigcharts.marketwatch.com ARQL Is expected to have larger losses in 2005 & 2006, but it has around $2.45 in cash/shr with a Debt/Equt around 0.001 a BV above $3 and some $9.7M in + cash flow.<g> Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next